When Targeted Therapy Enters the Discussion
How targeted treatment is chosen when peripheral SpA remains active, with clear distinctions between direct evidence, related-disease evidence and approval.
All chapters in this collection
Understanding the diagnosis
- 1. Peripheral SpA, Undifferentiated SpA and a Working Diagnosis
- 2. Joints, Entheses and Dactylitis: Understanding the Peripheral Pattern
- 3. How the Diagnosis Is Built
- 4. New Symptoms: What Changes the Picture and When Not to Wait
Tests and imaging
- 5. Blood Tests and HLA-B27: What They Can and Cannot Tell You
- 6. Ultrasound, MRI, X-ray and Joint Aspiration: Choosing the Right Test
Treatment decisions
- 7. What Are We Actually Trying to Improve?
- 8. NSAIDs, Local Treatment and Conventional DMARDs
- 9. When Targeted Therapy Enters the Discussion
Daily life and follow-up
- 10. Movement, Feet, Hands, Work and Everyday Load
- 11. How Do We Know Treatment Is Working?
- 12. Pregnancy, Infection, Surgery and Other Medical Conditions
When the picture changes
- 13. Why the Diagnosis May Change
- 14. When Pain, Examination, Blood Tests and Imaging Disagree
- 15. Remission, Treatment Reduction and Long-Term Outlook
Research and future care
A biologic or targeted medicine is not simply the next item on a ladder of “stronger” drugs. The question is whether a particular immune pathway is a useful treatment target for your active disease, and whether the expected benefit justifies the risks and practical demands.
First confirm what needs treatment
Persistent swollen joints, inflammatory enthesitis or dactylitis may justify a discussion of additional therapy. Before changing treatment, the team reviews the evidence for ongoing inflammation, the adequacy of previous treatment and possible competing explanations for symptoms.
Severe pain alone does not identify the best immune treatment. Pain from a damaged joint, tendon overload or an additional pain condition may need a different approach, even when SpA is also present. That reassessment is part of taking the symptoms seriously.
Direct evidence is available, but it is specific
TNF inhibitors block a signaling protein involved in inflammation. In the published ABILITY-2 randomized trial, adalimumab improved outcomes in adults with active nonpsoriatic peripheral SpA who had not responded adequately to, or could not tolerate, NSAIDs. This is direct evidence for a defined patient group, not proof that every person with an undifferentiated label should receive the same medicine.
The CRESPA trial studied golimumab in a much smaller group with very early peripheral disease. Its findings support further interest in early treatment strategies, but the population and question were different. Your clinician should distinguish treatment of established persistent disease from an early-intervention research strategy.
Related diseases help inform decisions
Several targeted pathways are established in PsA or axial SpA, including TNF, IL-17 and other immune targets. Some oral targeted medicines act through JAK pathways. Evidence for a class in one disease cannot be assumed to apply unchanged to all nonpsoriatic peripheral SpA.
Ask whether the proposed medicine has direct evidence for your pattern, is being chosen because a specific associated disease has been established, or relies partly on extrapolation. These are legitimate distinctions in the strength and applicability of the evidence, not simply different ways of advertising a drug.
Other organs can change the choice
Confirmed inflammatory bowel disease, important psoriasis or recurrent uveitis can affect treatment selection. The best option for a joint problem may not be the best option for the full person. Drugs within a broad class can also differ in approved uses and evidence for particular organs.
Coordination between rheumatology, gastroenterology, dermatology and ophthalmology can prevent separate prescriptions from pulling in different directions. Tell each clinician what the others are treating and share the actual diagnoses, not just symptoms that have not yet been assessed.
Evidence, approval and coverage are separate
A favorable trial result does not automatically create a regulatory indication. Approval in one country or for PsA does not automatically mean approval for isolated nonpsoriatic pSpA elsewhere. Insurance coverage adds another layer and may use criteria that differ from the clinical reasoning.
If use is off label, ask why it is reasonable, what evidence supports it and what alternatives exist. A biosimilar is also not an inherently weaker biologic: approved biosimilars must meet standards demonstrating no clinically meaningful differences from their reference product.
Prepare a practical safety and follow-up plan
Before treatment, ask about infection screening, vaccination, pregnancy plans, interactions and the monitoring appropriate to that drug. Discuss personal risks rather than treating all targeted agents as interchangeable. For example, selected JAK inhibitors carry specific FDA warnings that make cardiovascular, clotting, cancer and smoking history relevant to shared decisions.
Clarify how treatment is administered, what to do during suspected infection, and how response will be reviewed. Special situations covers those preparations. Reading new research explains how to interpret promising results while keeping their limits in view.
Sources and further reading
- ABILITY-2: Randomized adalimumab trial in nonpsoriatic peripheral SpA
- CRESPA: Anti-TNF-induced remission in very early peripheral SpA
- SPARTACUS: EULAR 2026 congress abstract OP0107
- American College of Rheumatology: Biosimilars, updated May 2026
- FDA safety communication on selected JAK inhibitors
- EULAR recommendations on antirheumatic drugs in reproduction, pregnancy and lactation: 2024 update, published 2025